Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.

Helliwell, Philip S

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. [electronic resource] - RMD open 02 2020

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

2056-5933

10.1136/rmdopen-2019-001149 doi


Adult
Antibodies, Monoclonal, Humanized--administration & dosage
Arthritis, Psoriatic--complications
Case-Control Studies
Female
HLA-B27 Antigen--drug effects
Humans
Injections, Subcutaneous
Interleukin-12--antagonists & inhibitors
Male
Middle Aged
Physicians--statistics & numerical data
Placebos--administration & dosage
Spondylitis--drug therapy
Tumor Necrosis Factor Inhibitors--administration & dosage
Ustekinumab--administration & dosage